Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, shared a post on X about a paper by Georgina Long et al. published in Nature Medicine:
“Breaking: Triple Checkpoint Blockade as Neoadjuvant Therapy in Glioblastoma – A New Frontier?
A new Nature Medicine study explores whether triple checkpoint blockade before surgery can increase immune response in GBM!
Objective:
- Assess if neoadjuvant anti-PD-1, anti-CTLA-4 and anti-LAG-3 improves immune activation and survival.
Methods:
- PH I/II trial in newly diagnosed GBM
- Treatment: Pre-op ICIs (anti-PD-1 + anti-CTLA-4 + anti-LAG-3) → Surgery → radiotherapy and TMZ
- Endpoints: Immune response, safety, OS, PFS
Key Results:
- increase T-cell infiltration in the tumor
- lower Immunosuppressive markers
- Safe and promising OS/PFS trends
Could neoadjuvant immunotherapy reshape GBM treatment? Thoughts?”
“Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma”
Authors: Georgina Long, Elena Shklovskaya, Laveniya Satgunaseelan, James Wilmott, Helen Rizos et al.
More posts featuring Gustavo Viani.
